bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

A Memoir by Texas-based author Jen Hatmaker, a “powerful memoir of self-discovery, authenticity and finding the courage to ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

A 17-year-old student at Brandywine High School is charged with splashing another student in the face with bleach at the school Wednesday morning. A school resource officer saw the incident happen ...

After hours: 7:51:56 p.m. EST ...

From peacekeeping on the Russia-Ukraine border to defending our own waters, experts say it can't come soon enough. Two defence experts are warning that New Zealand's ageing navy is woefully inadequate ...

I think this might be the first time I’ve ever seen a squirrel’s breath. It was sitting on a branch nibbling a spruce cone ...